Control
Recent:Dupuis.
Nov 3 2022 |
et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2022/3125662 | Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study |
| 209% higher progression (p=0.36) and 31% improved recovery (p=0.23). RCT 216 COVID-19 outpatients showing no significant difference in primary outcome (presence of fever, cough, shortness of breath, or anosmia) with hesperidin treatment versus placebo after 14 days, though a post-hoc sensitivity analysis s.. | ||
Oct 30 2020 |
et al., NCT04452799 | Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt |
| Estimated 100 patient hesperidin early treatment RCT with results not reported over 4 years after estimated completion. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.